Guardant Health, Inc. (NASDAQ:GH) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET

Company Participants

Zarak Khurshid - VP, IR
Helmy Eltoukhy - Co-CEO
AmirAli Talasaz - Co-CEO
Mike Bell - CFO

Conference Call Participants

Bill Bonello - Craig-Hallum
Mark Massaro - BTIG
Subbu Nambi - Guggenheim
Tycho Peterson - Jefferies
Puneet Souda - Leerink Partners
Kyle Mikson - Canaccord
Tejas Savant - Morgan Stanley
Dan Brennan - TD Cowen
Dan Arias - Stifel
Eve Burstein - Bernstein Research
Doug Schenkel - Wolfe Research

Operator

Hello, everyone, and welcome to the Guardant Health Q3 2024 Earnings Call. My name is Nadia and I will be coordinating the call today. [Operator Instructions].

I would now hand over to your host, Zarak Khurshid, Vice President of Investor Relations to begin. Zarak, please go ahead.

Zarak Khurshid

Thank you.

Earlier today, Guardant Health released financial results for the quarter ended September 30, 2024. Joining me today from Guardant are Helmy Eltoukhy, Co-CEO; AmirAli Talasaz, Co-CEO; and Mike Bell, Chief Financial Officer.

Before we begin, I'd like to remind you that, during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated.

This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specific items. Additional information regarding material risks and uncertainties, as well as the non-GAAP reconciliation to the most directly comparable GAAP financial measures are available in the press release Guardant issued today, as well as in our 10-K and other filings with the SEC.

Guardant disclaims any intention or obligation to update or revise financial projections and forward-looking statements whether because of new information, future events or otherwise except as required by law. The information in this conference call is accurate only as of the live broadcast.

With that, I would like to turn the call over to Helmy.

Helmy Eltoukhy

Thanks, Zarak. Good afternoon, and thank you for joining our third quarter 2024 earnings call.

Starting on Slide 3, 12 years ago, we embarked on our mission to conquer cancer with data. Roughly two years later, we launched into the late-stage cancer market with our first version of Guardant360 in 2014.

In 2021, we launched Guardant Reveal for cancer recurrence and monitoring. And this past quarter, on August 1, we were thrilled to launch our first test into the asymptomatic cancer screening market with Shield unlocking an exciting opportunity to potentially impact millions more individuals across the cancer continuum.